FBN2

Across TCGA pan-cancer cohorts, FBN2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated FBN2 data layer compared with 29 for mass-spec protein and 14 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher FBN2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated FBN2 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

PDAC, CCRCC, and HNSC are the cancer types where FBN2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.736	0.858	.022	12	view →
CCRCC	OS	Median	All	0.430	1.000	.016	7	view →
HNSC	OS	Quartile	All	0.352	1.000	.045	6	view →
GBM	DFS	Tertile	All	0.785	0.471	.013	3	view →
LSCC	OS	Median	All	0.784	0.946	.011	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

FBN2–PDAC (DFS)

Open the PDAC breakdown →